Supplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Year: 2026
Type: supplementary-materials
Abstract: Patient and baseline characteristics of GEICAM/9906 hormone receptor positive (HR+) breast cancer cohort.
Authors: Miguel Martín, Alvaro Rodriguez-Lescure, Cristina Reboredo, Eveline Chen, Manuel Ruiz-Borrego, Ana Santaballa Bertran, Cesar A. Rodríguez, Noelia Martinez-Jañez, Emilio Alba, Kevin Tran, Ignacio Pelaez Fernandez, Isabel Álvarez, Miguel A. Seguí, Alberto de la Cruz, Vicente Valero, Antonio Antón-Torres, Raquel Andrés, Kepa Amillano, José J. Ponce-Lorenzo, Severina Dominguez Fernandez, Jesus Herranz, Raul Rincon, Rosalía Caballero, Angel Guerrero-Zotano, Federico Rojo, W. Fraser Symmans
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7204935102